RxDoctor Payments Data

Ryan Mandell, DO

Clinical Cardiac Electrophysiology · Browns Mills, NJNPI 1598920183

Payments from drug & device makers

$3,676in general payments, 2019–2025

Across 79 payments — averaging $46.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Johnson & Johnson$305
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$238
  • Cardiva Medical, Inc.$219
  • Merck$144
  • Philips North America LLC$112
  • plus $444 from 10 others

What the payments were for

  • Travel & lodging$76521%
  • Food & beverage$2,91179%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,676 in reported general payments places this provider in the 10th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

See all clinical cardiac electrophysiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$231,954
Medicare patients
725
Services billed
3,599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban199$198,645
XareltoRivaroxaban74$64,635
MultaqDronedarone Hcl15$19,595
Flecainide Acetate235$9,978
Dofetilide79$7,959
Mexiletine Hcl18$2,897
Metoprolol Succinate197$2,539
SotalolSotalol Hcl95$1,630
Diltiazem 24hr Er (Cd)Diltiazem Hcl71$1,264
Diltiazem 24hr Er (La)Diltiazem Hcl13$862
Metoprolol Tartrate83$735
Diltiazem Hcl37$680
Nadolol12$649
Potassium Chloride39$613
Digoxin24$455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$56$198,645199 claims
Johnson & JohnsonXarelto$305$64,63574 claims
Sanofi-aventis U.S. LLCMultaq$35$19,59515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

Other clinical cardiac electrophysiology in Browns Mills

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →